Non-toxic dose chidamide synergistically enhances platinum-induced DNA damage responses and apoptosis in Non-Small-Cell lung cancer cells |
| |
Authors: | You Zhou De-Si Pan Song Shan Jing-Zhong Zhu Kun Zhang Xu-Peng Yue Li-Ping Nie Jun Wan Xian-Ping Lu Wei Zhang Zhi-Qiang Ning |
| |
Institution: | 1. Biomedical Research Institute, Shenzhen-PKU-HKUST Medical Center, Shenzhen, 518036 Guangdong, China;2. Chipscreen Biosciences Ltd., Bio-Incubator 2-601, 1st Ave. of Gaoxin Road, Hi-Tech Industrial Park, Shenzhen, 518057 Guangdong, China;3. Department of Clinical Laboratory, Shenzhen Hospital, Peking University, Guangdong, China |
| |
Abstract: | Combination of low doses of histone deacetylases inhibitors and chemotherapy drugs is considered as one of the most promising strategies to increase the anticancer efficacy. Chidamide is a novel benzamide chemical class of HDAC inhibitor that selectively inhibited HDAC1, 2, 3 and 10. We sought to determine whether chidamide may enhance platinum-induced cytotoxicity in NSCLC cells. In this study, the combination of chidamide with carboplatin showed a good synergism on growth inhibition with the mean combination index value as 0.712 and 0.639 in A549 and NCI-H157 cells, respectively. The used concentration of chidamide was non-toxic on cells by itself as low as 0.3 μM. All of our experiments were comparisons between combination regimen and single carboplatin regimen in A549 and NCI-H157 cell lines. Phosphorylated histone H2A.X (γH2A.X), a hall marker of DNA damage response, was dramatically increased by the combination treatment. Cell cycle analysis by flow cytometry and phosphorylation level analysis of histone H3 (Ser10) by western blotting showed that combination treatment significantly increased the percentage of G2/M phase of cells. Mitochondrial membrane potential and cleaved-PARP1 level analysis indicate that chidamide synergistically enhances carboplatin-induced apoptosis. Additionally, synergistic effects of chidamide were found when it was combined with two other platinum drugs (cisplatin and oxaliplatin). The results suggest that Chidamide in combination with platinum drugs may be a novel therapeutic option for NSCLC. |
| |
Keywords: | HDAC inhibitor Carboplatin Cisplatin Oxaliplatin DNA damage Non-small-cell lung cancer |
本文献已被 ScienceDirect 等数据库收录! |
|